-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
August 2021
-
Narjust Duma Moves to Dana-Farber Cancer Institute
Narjust Duma, MD, has been named associate director of the Cancer Care Equity Program and assistant professor of medicine at Dana-Farber Cancer Institute/Harvard Medical School. She will develop strategies to diminish health care disparities and enhance cancer care delivery while continuing her practice as a thoracic oncologist as well as her research, both of which…
-
Gemcitabine: A New Chemotherapy Partner for Immune Checkpoint Inhibitors? Insights From the ORIENT-12 Study
Squamous cell lung cancer (SqCLC), which accounts for approximately 25% to 30% of all lung cancer cases, is the second-most prevalent histologic subtype of NSCLC. Its distinct clinicopathologic and molecular characteristics present obstacles to the development of treatments for SqCLC, resulting in a poorer prognosis. It affects patients who are older, who have more comorbidities…
-
Peter Bach, MD, is the New Chief Medical Officer at Delfi Diagnostic
Peter Bach, MD, is the new chief medical officer at Delfi Diagnostics, a developer of blood tests for early detection of multiple types of cancer. Dr. Bach leaves Memorial Sloan Kettering after 23 years, where he served as director of the Center for Health Policy and Outcomes. “Lung cancer screening is the ideal place to…
-
Joshua Bauml, MD, moves to The Janssen Pharmaceutical Companies of Johnson & Johnson
Joshua Bauml, MD, has moved to The Janssen Pharmaceutical Companies of Johnson & Johnson from the University of Pennsylvania. Dr. Bauml was with the University of Pennsylvania for a decade—2 years as a fellow and 8 years as faculty—most recently servicing as an Assistant Professor of Medicine. Dr. Bauml will be joining the lung cancer…
-
Jean-Charles Soria, MD, PhD Joins Amgen
Jean-Charles Soria, MD, PhD, joined Amgen in early August 2021 as senior vice president of the oncology therapeutic sector. Prof. Soria, previously served as senior vice president of Research & Development in Oncology at AstraZeneca, where he was responsible for strategy and development of new immuno-oncology, cell therapy, and conjugated antibody agents. Most recently Dr.…
-
Suresh S. Ramalingam, MD, Appointed Executive Director of the Winship Cancer Institute and Associate Vice-President for Cancer at the Woodruff Health Sciences Center of Emory University
Suresh S. Ramalingam, MD, was appointed as the executive director of the Winship Cancer Institute and Associate Vice-President for Cancer at the Woodruff Health Sciences Center of Emory University on July 01, 2021. Previously he served as the deputy director of Winship Cancer Institute. Dr. Ramalingam is also the Roberto D. Goizueta distinguished chair for…
-
Telehealth Struggles to Find Permanent Footing After Rapid Growth During Pandemic
The ILCN is aware that the situation with telehealth differs across regions and that lack of access to technology is a huge obstacle. We would love to hear from IASLC members around the globe about your experiences. Please email us at [email protected].
-
Therapeutic Vaccine Development in Lung Cancer: Update and Recent Advances
Most cancer immunotherapies currently in development aim to stimulate antitumor T-cell responses either by adoptive transfer of in vitro expanded native or genetically modified T lymphocytes targeting malignant cells,1 ,2 administration of neutralizing monoclonal antibodies (mAb) specific to T-cell inhibitory receptors, such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed death-1 (PD-1),3 ,4 ,5 ,6 ,7…
-
Radiotherapy Inaccessibility in Lung Cancer Care: An Ongoing Crisis
A leading cause of mortality worldwide, cancer was tied to nearly 10 million deaths in 2020.1 Lung cancer has remained unchallenged for more than 30 years as the most commonly diagnosed malignancy and the leading cause of cancer mortality worldwide, accounting for up to 1.8 million deaths per year.2 ,3 Treatment for lung cancer depends…
-
Economics of Locally Advanced Lung Cancer Before and During COVID-19 Pandemic: A Perspective for Developing Countries
Since December 2019, the world has been mired in a pandemic that has displaced other 21st-century health priorities for many populations. The social significance and speed of contagion from COVID-19 have altered criteria for public health prioritization, to the detriment of other health problems including noncommunicable diseases, which are recognized as the leading cause of…
View ILCN Archives
Provider Resources
Popular Articles